Fusion glycoprotein F0

Fusion glycoprotein F0 Informations sur la molécule

Nom anglais	Respiratory syncytial virus F protein	Nombre de médicaments commercialisés	3
Nombre de médicaments cliniques	5	Alias de la cible	Protein F，F，Fusion glycoprotein F0
Phase de R&D la plus avancée	Approved

Nom anglais	Respiratory syncytial virus F protein
Alias de la cible	Protein F，F，Fusion glycoprotein F0
Nombre de médicaments commercialisés	3
Nombre de médicaments cliniques	5
Phase de R&D la plus avancée	Approved

Fusion glycoprotein F0 Liste de produits

Attribut
Antibody (2)Protein (1)
Bibliothèque de produits
En ligne (3)
Espèces
Mouse (2)Mumps virus (1)
Étiquette
- (2)His Tag & Avi Tag (1)
Marqueur
Unconjugated (2)Biotin-labeled (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
RSF-MY2092	Mouse	HEK293	Monoclonal Anti-Mumps virus Fusion glycoprotein F0 Antibody, Human IgG1 (5A3) (MALS verified)	Ajouter au panier
RSF-MY2093	Mouse	HEK293	Monoclonal Anti-Mumps virus Fusion glycoprotein F0 Antibody, Human IgG1 (8F8) (MALS verified)	Ajouter au panier
RSF-M82E3	Mumps virus	HEK293	Biotinylated Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0 Protein, His,Avitag™	Ajouter au panier

Quantité totale3

Fusion glycoprotein F0Contexte de la molécule

The two surface glycoproteins of the mumps virus are the hemagglutinin-neuraminidase (HN) and Fusion proteins. These glycoproteins are essential for viral entry to host cells, and the spread of newly formed virions. The mumps fusion protein (F) is a 538-amino acid, class one fusion surface glycoprotein. It is responsible for the membrane fusion of virus and host cell. The un-cleaved protein has three hydrophobic regions: an amino-terminal signal peptide, an amino terminal region of F1 and the carboxyl-terminal membrane domain. This protein starts as a precursor molecule (F0), and is then cleaved into the active protein by the recognition of a R-X-L/R-R motif by a host endoprotease (furin). The F protein contains two disulfide-linked polypeptides (F1 and F2).

Fusion glycoprotein F0Alias de la molécule

Fusion glycoprotein F0

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
CPI-RSV-F Vaccine	BLB-201	Phase 2 Clinical	Blue Lake Biotechnology Inc	Respiratory Syncytial Virus Infections	Details
RSV vaccine (Vaxart)		Phase 1 Clinical	Vaxart Biosciences Inc	Respiratory Syncytial Virus Infections	Details
GR-2102	GR2102; GR-2102	Phase 1 Clinical	Chongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd	Respiratory Syncytial Virus Infections	Details
Palivizumab biosimilar (mAbxience)	MB-05	Phase 1 Clinical	Mabxience Sa		Details
RSM-01		Phase 1 Clinical	Bill & Melinda Gates Medical Research Institute	Respiratory Syncytial Virus Infections	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Nirsevimab	Anti-RSV-mAb-D25; SP-0232; MEDI-8897; Anti-RSV MAb-YTE	Approved	Aimm Therapeutics, MedImmune Inc, Sanofi	Beyfortus, 乐唯初	EU	Respiratory Syncytial Virus Infections	Sanofi Winthrop Industrie SA	2022-10-31	Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections	Details
Palivizumab	ABT-315; MEDI-493	Approved	Abbvie Inc, Medimmune Llc	Synagis	United States	Respiratory Syncytial Virus Infections	Swedish Orphan Biovitrum Ab (Publ)	1998-06-19	Bronchiolitis; Bronchopulmonary Dysplasia; Heart Defects, Congenital; Infant, Premature, Diseases; Premature Birth; Respiratory Syncytial Virus Infections	Details
Respiratory syncytial virus immune globulin	RSV-IGIV	Approved	Medimmune	RespiGam	United States	Respiratory Syncytial Virus Infections	null	1996-01-01	Respiratory Syncytial Virus Infections	Details